Clinical commentary on prophylactic treatment of radiation-induced xerostomia

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 2, 2003, Pages 251-252

  Chambers, Mark S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTIOXIDANT; BUFFER; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; ELECTROLYTE; ENZYME; GROWTH FACTOR; IMMUNOGLOBULIN; MINERAL; PILOCARPINE; PROTEIN;

CELL LOSS; DNA DAMAGE; DRUG EFFICACY; GENE TRANSFER; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; MEDICAL TECHNOLOGY; NONHUMAN; PATHOGENESIS; PROPHYLAXIS; RADIATION DOSE; SALIVA ANALYSIS; SALIVARY GLAND; SHORT SURVEY; XEROSTOMIA;

EID: 0037319789     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.2.251     Document Type: Short Survey

References (2)

1. Scarantino CW, Leveque F, Scott C, et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck patients: final results of RTOG 97-09. Int J Radiat Oncol Biol Phys. 2001;51:85-86.
2. Warde P, Aslanidis J, Kroll B, et al. A phase III placebo controlled trial of oral pilocarpine in patients undergoing radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2001; 51:86.